Document Detail


Early clinical evaluation of the intravenous treatment of acute myocardial infarction with anisoylated plasminogen streptokinase activator complex.
MedLine Citation:
PMID:  3315575     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
50 consecutive patients with acute myocardial infarction and symptoms of less than 4 hours duration were treated with anisoylated plasminogen streptokinase activator complex (APSAC) 30U intravenously as a bolus injection over 5 minutes. An open infarct-related artery was found in 32 patients (64%) when the first coronary angiography was taken 66 +/- 21 minutes after APSAC. Complete reperfusion was subsequently seen in 10 of 18 patients with an occluded infarct-related artery 74 +/- 16 minutes after injection of APSAC. Thus, a patient infarct-related artery was seen in 42 patients (84%) within 68 +/- 20 minutes. A control coronary angiography was performed in 37 patients (74%) after 25 +/- 19 days. Reocclusion was found in 5 patients. The minimal cross-sectional area of the residual coronary stenosis increased from 1.3 +/- 0.9 mm2 to 1.8 +/- 1.9 mm2. Patients with residual thrombi after coronary thrombolysis (n = 13) demonstrated an increase of the minimal cross-sectional area of the residual stenosis from 1.2 +/- 0.8 to 2.6 +/- 2.3 mm2, whereas those without residual thrombi showed only minor changes of the minimal cross-sectional area (1.3 +/- 0.9 to 1.2 +/- 1.2 mm2). Thus, APSAC demonstrated a high patency rate and a low reocclusion rate after intravenous administration. The prolonged fibrinolytic activity of APSAC leads to a further regression of the residual coronary stenosis among patients with coronary thrombi after reperfusion.
Authors:
W Kasper; T Meinertz; H Wollschläger; T Bonzel; C Chen; T Hofmann; A Zeiher; H Drexler; H Just
Related Documents :
10822515 - Accelerated streptokinase--a new thrombolytic regimen in acute myocardial infarction.
7977615 - Streptokinase-induced tenon's hemorrhage after retinal detachment surgery.
15665255 - Magnesium deficiency in critical illness.
17670355 - Does magnesium prophylaxis reduce the incidence of atrial fibrillation following corona...
7921525 - Restacorin, a new antiarrhythmic drug: a review of its electrophysiologic and hemodynam...
2408785 - Fibrin formation and platelet aggregation in patients with severe coronary artery disea...
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Drugs     Volume:  33 Suppl 3     ISSN:  0012-6667     ISO Abbreviation:  Drugs     Publication Date:  1987  
Date Detail:
Created Date:  1988-01-07     Completed Date:  1988-01-07     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7600076     Medline TA:  Drugs     Country:  NEW ZEALAND    
Other Details:
Languages:  eng     Pagination:  112-6     Citation Subset:  IM    
Affiliation:
Klinikum der Albert-Ludwigs-Universität, Med. Universitäts Klinik, Abteilung Innere Medizin III, Kardiologie, Freiburg.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Anistreplase
Clinical Trials as Topic
Coronary Angiography
Coronary Circulation / drug effects
Female
Fibrinogen / metabolism
Fibrinolytic Agents / adverse effects,  therapeutic use*
Follow-Up Studies
Hemorrhage / chemically induced
Humans
Injections, Intravenous
Male
Middle Aged
Myocardial Infarction / drug therapy*
Plasminogen / adverse effects,  therapeutic use*
Streptokinase / adverse effects,  therapeutic use*
Vascular Patency / drug effects
Chemical
Reg. No./Substance:
0/Fibrinolytic Agents; 81669-57-0/Anistreplase; 9001-32-5/Fibrinogen; 9001-91-6/Plasminogen; EC 3.4.-/Streptokinase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Summary of early clinical experience with anisoylated plasminogen streptokinase activator complex in...
Next Document:  Achievement of coronary artery patency by use of anisoylated plasminogen streptokinase activator com...